Replication timing alterations in leukemia affect clinically relevant chromosome domains

Juan Carlos Rivera-Mulia; Takayo Sasaki; Claudia Trevilla Garcia; Naoto Nakamichi; David J.H.F. Knapp; Colin A. Hammond; Bill H. Chang; Jeffrey W. Tyner; Meenakshi Devidas; Jared Zimmerman; Kyle N. Klein; Vivek Somasundaram; Brian J. Druker; Tanja A. Gruber; Amnon Koren; Connie J. Eaves; David M. Gilbert

doi:10.1182/bloodadvances.2019000641

Replication timing alterations in leukemia affect clinically relevant chromosome domains

Juan Carlos Rivera-Mulia, Takayo Sasaki, Claudia Trevilla Garcia, Naoto Nakamichi, David J.H.F. Knapp, Colin A. Hammond, Bill H. Chang, Jeffrey W. Tyner, Meenakshi Devidas, Jared Zimmerman, Kyle N. Klein, Vivek Somasundaram, Brian J. Druker, Tanja A. Gruber, Amnon Koren, Connie J. Eaves, David M. Gilbert

Biochemistry, Molecular Biology, and Biophysics (TMED)

Research output: Contribution to journal › Article › peer-review

11 Scopus citations

Abstract

Human B-cell precursor acute lymphoid leukemias (BCP-ALLs) comprise a group of genetically and clinically distinct disease entities with features of differentiation arrest at known stages of normal B-lineage differentiation. We previously showed that BCP-ALL cells display unique and clonally heritable, stable DNA replication timing (RT) programs (ie, programs describing the variable order of replication and subnuclear 3D architecture of megabase-scale chromosomal units of DNA in different cell types). To determine the extent to which BCP-ALL RT programs mirror or deviate from specific stages of normal human B-cell differentiation, we transplanted immunodeficient mice with quiescent normal human CD34¹ cord blood cells and obtained RT signatures of the regenerating B-lineage populations. We then compared these with RT signatures for leukemic cells from a large cohort of BCP-ALL patients with varied genetic subtypes and outcomes. The results identify BCP-ALL subtype-specific features that resemble specific stages of B-cell differentiation and features that seem to be associated with relapse. These results suggest that the genesis of BCP-ALL involves alterations in RT that reflect biologically significant and potentially clinically relevant leukemia-specific epigenetic changes.

Original language	English (US)
Pages (from-to)	3201-3213
Number of pages	13
Journal	Blood Advances
Volume	3
Issue number	21
DOIs	https://doi.org/10.1182/bloodadvances.2019000641
State	Published - Nov 12 2019

Bibliographical note

Funding Information:
The authors thank R. Didier for expert help with flow cytometry, and M. Hale and G. Edin and the British Columbia Cancer Agency Stem Cell Assay Laboratory staff for technical assistance in CB cell processing and animal irradiations. This work was supported by National Institutes of Health (NIH), National Cancer Institute (NCI) grant R21 CA161666 and NIH, National Institute of General Medical Sciences grant R01 GM083337, and a Margaret and Mary Pfeiffer Professorship for Cancer Research (D.M.G.), a Terry Fox Foundation New Frontiers Program Project grant, and Canadian Cancer Research Society Research Institute grants (C.J.E.). D.J.H.F.K. held a Canadian Institutes of Health Research (CIHR) Vanier Scholarship, and C.A.H. held a CIHR Frederick Banting and Charles Best Doctoral Scholarship. Children’s Oncology Group trials were supported by NIH, NCI grants U10 CA98543, U10 CA98413, U10 CA180886, 1U24-CA196173, and U10 CA180899, and by St. Baldrick’s Foundation.

Publisher Copyright:
© 2019 by The American Society of Hematology

PubMed: MeSH publication types

Journal Article

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Publisher link

10.1182/bloodadvances.2019000641

Find It

Find It at U of M Libraries

Cite this

Rivera-Mulia, J. C., Sasaki, T., Trevilla Garcia, C., Nakamichi, N., Knapp, D. J. H. F., Hammond, C. A., Chang, B. H., Tyner, J. W., Devidas, M., Zimmerman, J., Klein, K. N., Somasundaram, V., Druker, B. J., Gruber, T. A., Koren, A., Eaves, C. J., & Gilbert, D. M. (2019). Replication timing alterations in leukemia affect clinically relevant chromosome domains. Blood Advances, 3(21), 3201-3213. https://doi.org/10.1182/bloodadvances.2019000641

Rivera-Mulia, JC, Sasaki, T, Trevilla Garcia, C, Nakamichi, N, Knapp, DJHF, Hammond, CA, Chang, BH, Tyner, JW, Devidas, M, Zimmerman, J, Klein, KN, Somasundaram, V, Druker, BJ, Gruber, TA, Koren, A, Eaves, CJ & Gilbert, DM 2019, 'Replication timing alterations in leukemia affect clinically relevant chromosome domains', Blood Advances, vol. 3, no. 21, pp. 3201-3213. https://doi.org/10.1182/bloodadvances.2019000641

@article{3e58afd37e40460bad9529ae4269e8b7,

title = "Replication timing alterations in leukemia affect clinically relevant chromosome domains",

abstract = "Human B-cell precursor acute lymphoid leukemias (BCP-ALLs) comprise a group of genetically and clinically distinct disease entities with features of differentiation arrest at known stages of normal B-lineage differentiation. We previously showed that BCP-ALL cells display unique and clonally heritable, stable DNA replication timing (RT) programs (ie, programs describing the variable order of replication and subnuclear 3D architecture of megabase-scale chromosomal units of DNA in different cell types). To determine the extent to which BCP-ALL RT programs mirror or deviate from specific stages of normal human B-cell differentiation, we transplanted immunodeficient mice with quiescent normal human CD341 cord blood cells and obtained RT signatures of the regenerating B-lineage populations. We then compared these with RT signatures for leukemic cells from a large cohort of BCP-ALL patients with varied genetic subtypes and outcomes. The results identify BCP-ALL subtype-specific features that resemble specific stages of B-cell differentiation and features that seem to be associated with relapse. These results suggest that the genesis of BCP-ALL involves alterations in RT that reflect biologically significant and potentially clinically relevant leukemia-specific epigenetic changes.",

author = "Rivera-Mulia, {Juan Carlos} and Takayo Sasaki and {Trevilla Garcia}, Claudia and Naoto Nakamichi and Knapp, {David J.H.F.} and Hammond, {Colin A.} and Chang, {Bill H.} and Tyner, {Jeffrey W.} and Meenakshi Devidas and Jared Zimmerman and Klein, {Kyle N.} and Vivek Somasundaram and Druker, {Brian J.} and Gruber, {Tanja A.} and Amnon Koren and Eaves, {Connie J.} and Gilbert, {David M.}",

note = "Funding Information: The authors thank R. Didier for expert help with flow cytometry, and M. Hale and G. Edin and the British Columbia Cancer Agency Stem Cell Assay Laboratory staff for technical assistance in CB cell processing and animal irradiations. This work was supported by National Institutes of Health (NIH), National Cancer Institute (NCI) grant R21 CA161666 and NIH, National Institute of General Medical Sciences grant R01 GM083337, and a Margaret and Mary Pfeiffer Professorship for Cancer Research (D.M.G.), a Terry Fox Foundation New Frontiers Program Project grant, and Canadian Cancer Research Society Research Institute grants (C.J.E.). D.J.H.F.K. held a Canadian Institutes of Health Research (CIHR) Vanier Scholarship, and C.A.H. held a CIHR Frederick Banting and Charles Best Doctoral Scholarship. Children{\textquoteright}s Oncology Group trials were supported by NIH, NCI grants U10 CA98543, U10 CA98413, U10 CA180886, 1U24-CA196173, and U10 CA180899, and by St. Baldrick{\textquoteright}s Foundation. Publisher Copyright: {\textcopyright} 2019 by The American Society of Hematology",

year = "2019",

month = nov,

day = "12",

doi = "10.1182/bloodadvances.2019000641",

language = "English (US)",

volume = "3",

pages = "3201--3213",

journal = "Blood Advances",

issn = "2473-9529",

publisher = "American Society of Hematology",

number = "21",

}

TY - JOUR

T1 - Replication timing alterations in leukemia affect clinically relevant chromosome domains

AU - Rivera-Mulia, Juan Carlos

AU - Sasaki, Takayo

AU - Trevilla Garcia, Claudia

AU - Nakamichi, Naoto

AU - Knapp, David J.H.F.

AU - Hammond, Colin A.

AU - Chang, Bill H.

AU - Tyner, Jeffrey W.

AU - Devidas, Meenakshi

AU - Zimmerman, Jared

AU - Klein, Kyle N.

AU - Somasundaram, Vivek

AU - Druker, Brian J.

AU - Gruber, Tanja A.

AU - Koren, Amnon

AU - Eaves, Connie J.

AU - Gilbert, David M.

N1 - Funding Information: The authors thank R. Didier for expert help with flow cytometry, and M. Hale and G. Edin and the British Columbia Cancer Agency Stem Cell Assay Laboratory staff for technical assistance in CB cell processing and animal irradiations. This work was supported by National Institutes of Health (NIH), National Cancer Institute (NCI) grant R21 CA161666 and NIH, National Institute of General Medical Sciences grant R01 GM083337, and a Margaret and Mary Pfeiffer Professorship for Cancer Research (D.M.G.), a Terry Fox Foundation New Frontiers Program Project grant, and Canadian Cancer Research Society Research Institute grants (C.J.E.). D.J.H.F.K. held a Canadian Institutes of Health Research (CIHR) Vanier Scholarship, and C.A.H. held a CIHR Frederick Banting and Charles Best Doctoral Scholarship. Children’s Oncology Group trials were supported by NIH, NCI grants U10 CA98543, U10 CA98413, U10 CA180886, 1U24-CA196173, and U10 CA180899, and by St. Baldrick’s Foundation. Publisher Copyright: © 2019 by The American Society of Hematology

PY - 2019/11/12

Y1 - 2019/11/12

N2 - Human B-cell precursor acute lymphoid leukemias (BCP-ALLs) comprise a group of genetically and clinically distinct disease entities with features of differentiation arrest at known stages of normal B-lineage differentiation. We previously showed that BCP-ALL cells display unique and clonally heritable, stable DNA replication timing (RT) programs (ie, programs describing the variable order of replication and subnuclear 3D architecture of megabase-scale chromosomal units of DNA in different cell types). To determine the extent to which BCP-ALL RT programs mirror or deviate from specific stages of normal human B-cell differentiation, we transplanted immunodeficient mice with quiescent normal human CD341 cord blood cells and obtained RT signatures of the regenerating B-lineage populations. We then compared these with RT signatures for leukemic cells from a large cohort of BCP-ALL patients with varied genetic subtypes and outcomes. The results identify BCP-ALL subtype-specific features that resemble specific stages of B-cell differentiation and features that seem to be associated with relapse. These results suggest that the genesis of BCP-ALL involves alterations in RT that reflect biologically significant and potentially clinically relevant leukemia-specific epigenetic changes.

AB - Human B-cell precursor acute lymphoid leukemias (BCP-ALLs) comprise a group of genetically and clinically distinct disease entities with features of differentiation arrest at known stages of normal B-lineage differentiation. We previously showed that BCP-ALL cells display unique and clonally heritable, stable DNA replication timing (RT) programs (ie, programs describing the variable order of replication and subnuclear 3D architecture of megabase-scale chromosomal units of DNA in different cell types). To determine the extent to which BCP-ALL RT programs mirror or deviate from specific stages of normal human B-cell differentiation, we transplanted immunodeficient mice with quiescent normal human CD341 cord blood cells and obtained RT signatures of the regenerating B-lineage populations. We then compared these with RT signatures for leukemic cells from a large cohort of BCP-ALL patients with varied genetic subtypes and outcomes. The results identify BCP-ALL subtype-specific features that resemble specific stages of B-cell differentiation and features that seem to be associated with relapse. These results suggest that the genesis of BCP-ALL involves alterations in RT that reflect biologically significant and potentially clinically relevant leukemia-specific epigenetic changes.

UR - http://www.scopus.com/inward/record.url?scp=85074933729&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85074933729&partnerID=8YFLogxK

U2 - 10.1182/bloodadvances.2019000641

DO - 10.1182/bloodadvances.2019000641

M3 - Article

C2 - 31698451

AN - SCOPUS:85074933729

SN - 2473-9529

VL - 3

SP - 3201

EP - 3213

JO - Blood Advances

JF - Blood Advances

IS - 21

ER -

Replication timing alterations in leukemia affect clinically relevant chromosome domains

Abstract

Bibliographical note

PubMed: MeSH publication types

UN SDGs

Publisher link

Find It

Other files and links

Fingerprint

Cite this